Brachytherapy

Papers
(The TQCC of Brachytherapy is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Editorial Board39
Editorial Board33
PO024930
PO032418
MPP02 Presentation Time: 4:09 PM18
PO042518
PPP02 Presentation Time: 10:39 AM16
PO022714
BP08 Presentation Time: 5:03 PM14
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM13
PO041713
BP02 Presentation Time: 4:09 PM13
PPP03 Presentation Time: 10:48 AM13
PSOR03  Presentation Time: 12:10 PM12
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM12
PSOR12  Presentation Time: 5:25 PM12
PHSOR06 Presentation Time: 9:25 AM12
PO9311
PO4711
PSOR8  Presentation Time: 12:05 PM10
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost10
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy10
Evaluation of variability in applicator position and organs at risk dose in fractionated intracavitary brachytherapy for cervical cancer10
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications10
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po10
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data10
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial10
PO3510
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study10
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy10
GPP03  Presentation Time: 9:33 AM9
PO219
GSOR04  Presentation Time: 12:15 PM9
PO46  Presentation Time: 4:45 PM9
P01059
PHSOP2  Presentation Time: 9:05 AM9
PO209
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM8
PL02  Presentation Time: 1:45 PM8
PP02  Presentation Time: 9:10 AM8
GSOR14  Presentation Time: 11:35 AM8
PSOR02  Presentation Time: 4:35 PM8
PO108
MSPP03  Presentation Time: 4:20 PM8
The case for risk-stratified IORT for early breast cancer7
PHSOR05  Presentation Time: 12:50 PM7
Table of Contents7
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?7
Determination of the optimal time for planning SAVI brachytherapy for APBI7
Table of Contents7
High-dose-rate brachytherapy for airway malignancy a single institution experience7
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer7
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life7
PHSOR04  Presentation Time: 12:45 PM7
Masthead7
PP05  Presentation Time: 5:06 PM7
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma7
Partial breast irradiation: An updated consensus statement from the American brachytherapy society6
PPP04  Presentation Time: 10:57 AM6
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes6
PL02 Presentation Time: 1:45 PM6
Comparison of novel shielded nasopharynx applicator designs for intracavitary brachytherapy6
PRPP05  Presentation Time: 11:06 AM6
Author Index6
MSOR11 Presentation Time: 8:50 AM6
PO02346
MSOR12 Presentation Time: 8:55 AM6
P03016
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients6
PO04216
Masthead6
PO02425
PHSOR06  Presentation Time: 12:55 PM5
A primer on time-driven activity-based costing in brachytherapy5
PO195
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy5
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing5
Skin Posters PO07015
PO01195
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM5
Increasing global access to brachytherapy: The ABS 300 in 10 initiative and ongoing international efforts5
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT5
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
PO02415
PO01095
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle5
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma5
PSOR02 Presentation Time: 11:35 AM5
Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer5
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review5
US-guided versus US-assisted tandem insertion for cervical cancer: A nomenclature proposal5
PO04245
PSOR3  Presentation Time: 11:40 AM4
Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy4
MSOP06  Presentation Time: 8:25 AM4
GPP06  Presentation Time: 11:15 AM4
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up4
Randomized trial comparing hypnosis versus standard management on patient anxiety and pain during pelvic brachytherapy applicator removal4
MPP02  Presentation Time: 4:09 PM4
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting4
PP04  Presentation Time: 9:47 AM4
PP05  Presentation Time: 11:36 AM4
PO534
GSOR13  Presentation Time: 12:30 PM4
PO914
PO154
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent4
PO40  Presentation Time: 4:45 PM4
PO524
PO864
MSOP03  Presentation Time: 8:10 AM4
PO1144
PP02  Presentation Time: 10:09 AM4
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy4
PO33  Presentation Time: 10:30 AM4
PO04083
PO02583
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy3
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
Dosimetric characterization and experimental validation for a low-kV FPXS electronic brachytherapy system3
MSOR11 Presentation Time: 5:50 PM3
PO02613
Laminaria tent insertion in preplanning MRI for CT-based cervical cancer brachytherapy3
PRSOP08  Presentation Time: 12:05 PM3
GSOR09 Presentation Time: 12:10 PM3
PRPP02  Presentation Time: 10:39 AM3
GYN Posters PO013
GSOR10 Presentation Time: 12:15 PM3
PO123
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer3
PO02203
PRSOP03  Presentation Time: 11:40 AM3
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
Demographic and clinical factors associated with variations in opioid administration using conscious sedation during HDR brachytherapy for cervical cancer3
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer3
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer3
GPP04  Presentation Time: 9:42 AM3
PP04  Presentation Time: 11:27 AM3
PO03113
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward3
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma3
PPP05 Presentation Time: 11:06 AM3
MSOR9 Presentation Time: 5:40 PM3
PO03203
PO01103
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
PSOR7  Presentation Time: 12:00 PM3
P03043
PO323
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities2
PL03 Presentation Time: 2:00 PM2
Actinium-225 Targeted Agents: Where Are We Now?2
GSOR06 Presentation Time: 5:25 PM2
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy2
PO03102
PO042
PHSOP6  Presentation Time: 9:25 AM2
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment2
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry2
Outcomes and comparison of dosimetric parameters between intracavitary (Fletcher) and combined intracavitary/interstitial (Utrecht) brachytherapy in locally advanced cervical cancer2
MSS11  Presentation Time: 4:35 PM2
PO822
Letter to the editor regarding “Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy”2
PHSOR08  Presentation Time: 1:05 PM2
P01142
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
PO1122
GSOR23  Presentation Time: 12:20 PM2
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion2
PO01112
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
Brachytherapy for rectal and anal cancer: Where are we and current perspectives?2
GSOR06  Presentation Time: 11:55 AM2
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
PO02332
PSA: Declining utilization of prostate brachytherapy2
MSOR7 Presentation Time: 5:30 PM2
PO102
PP02  Presentation Time: 8:29 AM2
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital2
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy2
PO492
What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?2
PO27  Presentation Time: 7:40 AM2
GSOR02  Presentation Time: 11:35 AM2
MPP05  Presentation Time: 4:36 PM2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
GSOR20  Presentation Time: 12:05 PM2
Table of Contents2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities2
GSOR12 Presentation Time: 5:55 PM2
Systematic review of brachytherapy for symptom palliation2
PSOR06  Presentation Time: 12:25 PM2
PO02292
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
PO03142
Editorial Board2
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada2
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
Masthead2
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
Table of Contents2
Masthead2
Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer2
MSPP05  Presentation Time: 4:40 PM2
PPP03  Presentation Time: 10:48 AM2
PL04  Presentation Time: 2:15 PM2
PO04282
Feasibility of internal-source tracking with C-arm CT/SPECT imaging with limited-angle projection data for online in vivo dose verification in brachytherapy: A Monte Carlo simulation study2
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer2
PO02481
Escalating the dose of high-dose-rate brachytherapy combined with external beam radiotherapy improves the disease control rate in patients with high- or very-high-risk prostate cancer1
Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer1
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques1
Radiation dose rate variations in different measurement scenarios after prostate 125I brachytherapy1
MPP03  Presentation Time: 4:18 PM1
PO111
PO191
Masthead1
GPP06  Presentation Time: 10:00 AM1
PO02401
PO30  Presentation Time: 10:30 AM1
Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retr1
Local seed displacement from Day 0 to Day 30 in I-125 permanent prostate brachytherapy: A detailed, computed tomography-based analysis1
Long-term disease-free survival following salvage brachytherapy for recurrent pediatric rhabdomyosarcoma: Two case reports and review of relevant literature1
Brachytherapy outcome modeling in cervical cancer patients: A predictive machine learning study on patient-specific clinical, physical and dosimetric parameters1
MSOP04  Presentation Time: 5:15 PM1
PO061
MSOR3  Presentation Time: 4:55 PM1
PPP02  Presentation Time: 10:39 AM1
Image-guided brachytherapy following external-beam radiation therapy for patients with inoperable endometrial cancer1
P01171
PO901
Table of Contents1
PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study1
Therapeutic and prophylactic effects of radiation therapy in the management of recurrent granulation tissue induced tracheal stenosis: a review on the role of Endobronchial brachytherapy and external 1
Inter-observer effects in needle reconstruction for temporary prostate brachytherapy: Dosimetric implications and adaptive CBCT-TRUS registration solutions1
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy1
PO271
MSOR05  Presentation Time: 8:50 AM1
PP05  Presentation Time: 4:06 PM1
MSOP01  Presentation Time: 8:00 AM1
Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization1
PPP01  Presentation Time: 4:00 PM1
0.076914072036743